TrialCancer2015

Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.

Mehmet Asim Bilen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.